The mOS of ramucirumab combined with pembrolizumab was only 6.44 months, which did not show a significant improvement in survival rate, whereas the mOS of PD-L1 positive patients was 11.33 months 35, suggesting that PD-L1 positive can serve as a tumor marker to provide a reference for the designation of future immunotherapy methods. This evidence concerns the gene CD274 and neoplasm.